Viracta Therapeutics
Latest round
- Series E
Last raised
- Nov 2020
Total raised
- $118M
Investors
- 11
About Viracta Therapeutics
, formerly known as HemaQuest Pharmaceuticals, Inc. is a precision oncology company that focuses on virus-related diseases., is the current President and Chief Executive Officer of the company. In 2020, Sunesis Pharmaceuticals, Inc. The company offers a combination approach to treat a range of viral-associated cancers and other serious diseases. Viracta’s proprietary investigational drug called nanatinostat in combination with the antiviral agent valganciclovir is a novel therapeutic approach to targeting EBV+ lymphoma. The company is also looking at using its inducible synthetic lethality technique in other EBV-related diseases, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers. Following the merger with Sunesis Pharmaceuticals, the company intends to continue advancing and expanding Viracta's clinical-stage pipeline, including Viracta's lead program for the treatment of Epstein-Barr virus (EBV)-positive lymphoma.
Who invested in Viracta Therapeutics
11 investors across 8 rounds
See all investors in Viracta Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series E
Nov 25, 2020
Amount
$40M
Investors
Series D
Oct 28, 2019
Amount
$17M
Investors
Series B
Apr 4, 2017
Amount
$18M
Investors
Series B
Mar 12, 2012
Amount
$6.5M
Investors
Series B
Jul 28, 2010
Amount
$4M
Investors
Series B
Apr 19, 2010
Amount
$6M
Investors
Series B
Jan 29, 2010
Amount
$6M
Investors
Series A
Nov 1, 2007
Amount
$20M
Investors
Questions about Viracta Therapeutics
Who invested in Viracta Therapeutics?
Viracta Therapeutics has 11 investors on record across 8 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Viracta Therapeutics raised?
Viracta Therapeutics has raised 8 venture rounds. Sign up free to see how much each round raised and the total.
When did Viracta Therapeutics last raise money?
Viracta Therapeutics's most recent round on record is a Series E, in Nov 2020.
What does Viracta Therapeutics do?
, formerly known as HemaQuest Pharmaceuticals, Inc.
Where is Viracta Therapeutics headquartered?
Viracta Therapeutics is headquartered in US.
Which VCs invest in companies like Viracta Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Viracta Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like Viracta Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.